Clinical Trials
7 trialsNCT02242045 2021-03-19
Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL)
Gilead Sciences
Phase 1 Completed
NCT01088048 2021-03-18
Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
Gilead Sciences
Phase 1 Completed
NCT02779283 2020-05-26
Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia
OHSU Knight Cancer Institute
Phase 1 Completed
NCT02603445 2020-02-24
Study of Safety and Efficacy of BCL201 and Idelalisib in Patients With FL and MCL
Novartis
Phase 1 Completed
NCT01644799 2018-01-30
Lenalidomide and Idelalisib in Treating Patients With Recurrent Follicular Lymphoma
Alliance for Clinical Trials in Oncology
Phase 1 Completed
NCT01838434 2018-01-30
Lenalidomide With or Without Idelalisib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
Alliance for Clinical Trials in Oncology
Phase 1 Completed
NCT00710528 2012-08-31
Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies
Gilead Sciences
Phase 1 Completed